Abstract
Accurate estimates of incidence over time are essential for investigating etiology. For diseases and disorders of early childhood, including autism and intellectual disability, birth year cohort prevalence serves as incidence. There is substantial uncertainty regarding the birth prevalence trend of autism, which is a disorder that results in a lifetime of reduced quality of life and is apparently increasingly prevalent world-wide. This paper presents a novel method to accurately estimate the true birth prevalence of autism and other childhood disorders.
Estimates based on summarizing available data may have substantial errors if the proportion of cases counted in the data changed over time because of changes in diagnostic factors. Controlling directly for diagnostic factors may lead to erroneous estimates. We have not found any existing method for robust estimation of birth prevalence while accounting for changing diagnostic factors. A novel method, Time-to-Event Prevalence Estimation (TTEPE), addresses this need. TTEPE extends established time-to-event analysis techniques. Input data are rates of initial diagnosis by diagnostic year and age for each birth cohort. Diagnostic factors form diagnostic pressure, which is the probability of diagnosing cases. Diagnostic pressure is a function of diagnostic year. Changes in diagnostic criteria may also change the effective prevalence at known times. Non-linear regression estimates parameters using a discrete survival model of the rate of initial diagnoses as a function of birth year, diagnostic year, and age. Diagnosable symptoms may develop with age, affecting eligibility for diagnosis. The paper states the assumptions underlying the analysis. A simulation study validates the TTEPE method, producing accurate estimates of parameters describing trends in birth prevalence and diagnostic pressure. The paper explores optional additional analyses and deviations from assumptions. TTEPE is a robust method for estimating trends in true case birth prevalence controlled for diagnostic factors and changes in diagnostic criteria under certain specified assumptions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos